3rd World ADC Asia

Antibody drug conjugate drug development in Asia has seen strong growth over the past year, with the Japanese-born Enhertu reaching blockbuster status. In 2023, Asia accounted for half of all new ADC clinical trials, surpassing the number of those from the US for 5 years in a row.

Across three packed days, with the highest quality industry speakers, attendees can join the likes of Daiichi Sankyo, Eisai, Shanghai Miracogen, OBI Pharma, Pinotbio, Pfizer, Hummingbird Biosciences, and many others in the APAC region paving the way to innovations. From new approaches to conjugation platforms, tackling challenges within clinical trials of Asian populations, navigating partnering with a CDMO, all with the continued goal of maximizing the therapeutic window of ADCs.